Bayer Diagnostics has announced the availability of its new Tnl-Ultra Troponin assay on the Advia Centaur CP Immunoassay system
TnI-Ultra assays aid physicians in the diagnosis of myocardial infarction and in the assessment of risk in patients with acute coronary syndrome.
The assays are the first fully-automated troponin assays to meet the European Society of Cardiology/American College of Cardiology recommendation of a <10% level of imprecision at the 99th percentile of a healthy population.
Meeting the ESC/ACC criteria is a key attribute in the definition of a high sensitivity Troponin test.
The launch of the TnI-Ultra assay on the Advia Centaur CP provides additional options for high sensitivity troponin testing on Bayer's immunoassay systems.
The TnI-Ultra assay was released earlier this year for the Advia Centaur and Advia IMS.
"Having multiple system options for cardiovascular testing that provide concordant results is extremely important because as patients move throughout the system, the need for rebaselining or repeat testing is minimised.
"The Advia Centaur CP TnI-Ultra assay is highly concordant with the Advia Centaur and Advia IMS TnI-Ultra assays.
"This makes the laboratory's life and the physician's life easier," stated Charaf Ahnadi, clinical trial investigator for the Advia Centaur CP TnI-Ultra assay, Centre de Biotechnologie de Sherbrooke, Canada.
